Lifeline Biotechnologies Stock Fundamentals
LLBO Stock | USD 0.0001 0.0003 75.00% |
Lifeline Biotechnologies fundamentals help investors to digest information that contributes to Lifeline Biotechnologies' financial success or failures. It also enables traders to predict the movement of Lifeline Pink Sheet. The fundamental analysis module provides a way to measure Lifeline Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lifeline Biotechnologies pink sheet.
Lifeline |
Lifeline Biotechnologies Company Net Income Analysis
Lifeline Biotechnologies' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Lifeline Biotechnologies Net Income | (574.27 K) |
Most of Lifeline Biotechnologies' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lifeline Biotechnologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition |
Based on the recorded statements, Lifeline Biotechnologies reported net income of (574,268). This is 100.17% lower than that of the Healthcare sector and 100.24% lower than that of the Medical Devices industry. The net income for all United States stocks is 100.1% higher than that of the company.
Lifeline Biotechnologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lifeline Biotechnologies's current stock value. Our valuation model uses many indicators to compare Lifeline Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lifeline Biotechnologies competition to find correlations between indicators driving Lifeline Biotechnologies's intrinsic value. More Info.Lifeline Biotechnologies is rated fifth overall in current valuation category among its peers. It is currently regarded as number one stock in net income category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Lifeline Biotechnologies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lifeline Biotechnologies' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Lifeline Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lifeline Biotechnologies' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Lifeline Biotechnologies could also be used in its relative valuation, which is a method of valuing Lifeline Biotechnologies by comparing valuation metrics of similar companies.Lifeline Biotechnologies is currently under evaluation in net income category among its peers.
Lifeline Fundamentals
Current Valuation | 4.25 M | |||
Net Income | (574.27 K) | |||
Cash And Equivalents | 603.32 K | |||
Total Debt | 448.07 K | |||
Debt To Equity | 0.08 % | |||
Current Ratio | 8.42 X | |||
Book Value Per Share | 0 X | |||
Beta | -1.86 | |||
Market Capitalization | 10.99 M | |||
Total Asset | 6.72 M | |||
Z Score | 14.4 | |||
Net Asset | 6.72 M |
About Lifeline Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lifeline Biotechnologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifeline Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifeline Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Lifeline Biotechnologies, Inc. is headquartered in Reno, Nevada. Lifeline Biotech operates under Medical Devices classification in the United States and is traded on OTC Exchange.
Pair Trading with Lifeline Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifeline Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifeline Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving against Lifeline Pink Sheet
0.57 | BSX | Boston Scientific Corp | PairCorr |
0.48 | EW | Edwards Lifesciences Corp | PairCorr |
0.47 | DXCM | DexCom Inc | PairCorr |
0.45 | SYK | Stryker | PairCorr |
0.43 | BRK-A | Berkshire Hathaway | PairCorr |
The ability to find closely correlated positions to Lifeline Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifeline Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifeline Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifeline Biotechnologies to buy it.
The correlation of Lifeline Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifeline Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifeline Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifeline Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Lifeline Pink Sheet
Lifeline Biotechnologies financial ratios help investors to determine whether Lifeline Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lifeline with respect to the benefits of owning Lifeline Biotechnologies security.